Arcus Biosciences reported total revenues of $67 million for the nine months ended September 30, 2026, a significant decrease from $214 million in the prior year period, primarily due to lower license and development services revenue. The company recorded a net loss of $347 million for the first nine months of 2026, compared to a net loss of $247 million in 2025, as operating expenses continued to outpace revenue.
Arcus Biosciences reported third-quarter 2026 financial results, ending the period with $694 million in cash and marketable securities. The company highlighted clinical progress for its HIF-2α inhibitor, casdatifan, with Phase 3 enrollment for the PEAK-1 study in kidney cancer expected to complete within three months.
“In October, we showed for the first time that robust and durable HIF-2α inhibition from casdatifan can address the needs of patients at every line of kidney cancer therapy: rapid and sustained disease control in the first line, durable benefit and potential survival advantage in the second line, even after a prior TKI-inclusive therapy, and nearly three years of median overall survival in late-line patients who had exhausted multiple therapies.”
Terry Rosen, Ph.D., chief executive officer of Arcus
“With PEAK-1 enrollment nearing completion and PEAK-20 set to begin by year-end, we are building the registrational evidence to make casdatifan the backbone of treatment across the continuum of care for clear cell renal cell carcinoma.”
Terry Rosen, Ph.D., chief executive officer of Arcus
Arcus Biosciences completed a public offering of 16,428,572 shares of common stock, including the full exercise of the underwriters' option to purchase additional shares. The offering was priced at $17.50 per share, resulting in net proceeds of approximately $269.7 million after fees and expenses.
Value
$288M
Counterparty
Jefferies LLC, Leerink Partners LLC and TD Securities (USA) LLC
Arcus Biosciences provided a preliminary estimate of its cash position, reporting approximately $694.0 million in cash, cash equivalents, and marketable securities as of September 30, 2026. This figure is an unaudited estimate released ahead of the company's full quarterly financial results.
Arcus Biosciences presented new data from its ARC-20 platform study evaluating casdatifan in various treatment lines for clear cell renal cell carcinoma (ccRCC). Key results included a 50% confirmed objective response rate (cORR) for the first-line casdatifan plus zimberelimab combination and a 14.5-month median progression-free survival for the second-line combination with cabozantinib.